ESTRO Brachytherapy for Prostate Cancer 2018

Summary

⚫ Long-term morbidity rate is low. (LoE: III) ⚫ Technical advances improve tumor control and lower toxicity. ⚫ Careful patient selection is important to avoid unacceptable morbidity ⚫ Urgent need for prospective trials to investigate on medical approaches to the treatment of morbidity.